bluebird bio Revenue and Competitors

Boston, MA USA

Location

$484M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • bluebird bio's estimated annual revenue is currently $53.6M per year.(i)
  • bluebird bio received $632.5M in venture funding in July 2018.
  • bluebird bio's estimated revenue per employee is $90,778
  • bluebird bio's total funding is $484M.
  • bluebird bio's current valuation is $612M. (January 2022)

Employee Data

  • bluebird bio has 591 Employees.(i)
  • bluebird bio grew their employee count by 6% last year.

bluebird bio's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
SVP Marketing, Sales, Strategy and AnalyticsReveal Email/Phone
3
Head, US BusinessReveal Email/Phone
4
VP Process, Data, and Manufacturing Sciences (Severe Genetic Diseases)Reveal Email/Phone
5
VP Head Information Technology and InformaticsReveal Email/Phone
6
SVP QualityReveal Email/Phone
7
VP, Commercial, OncologyReveal Email/Phone
8
VP, Value Demonstration and Access StrategyReveal Email/Phone
9
VP, Analytical DevelopmentReveal Email/Phone
10
VP, Oncology Corporate DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is bluebird bio?

We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$484M

Total Funding

591

Number of Employees

$53.6M

Revenue (est)

6%

Employee Growth %

$612M

Valuation

N/A

Accelerator

bluebird bio News

2022-04-20 - Bluebird bio's gene therapy Zynteglo could have high price ...

Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...

2022-04-17 - Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash

Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...

2022-03-30 - Bluebird bio cuts 30% of its workforce as gene therapy dreams ...

The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...

2021-09-08 - bluebird bio : Secures $75 Million in Private Placement Equity Financing

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...

2021-06-07 - BLUEBIRD BIO, INC. Bluebird bio : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies (Form 8-K)

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$214.2M5916%N/A
#2
$188.9M59516%N/A
#3
$167.2M6088%N/A
#4
$140.2M62313%N/A
#5
$140.2M62313%N/A

bluebird bio Funding

DateAmountRoundLead InvestorsReference
2011-04-21$30.0MUndisclosedARCH Venture Partners, Third Rock VenturesArticle
2012-07-26$60.0MDDeerfield Partners, RA CapitalArticle
2013-06-03$60.0MDDeerfield Partners, RA CapitalArticle
2014-12-17$150.0MUndisclosedArticle
2015-06-25$575.0MBofA Merrill LynchArticle
2016-12-08$200.0MUndisclosedGoldman, Sachs & CoArticle
2017-06-28$350.0MUndisclosedGoldman Sachs & Co. LLCArticle
2017-12-14$600.0MUndisclosedMultipleArticle
2018-01-10$651.3MUndisclosedMultipleArticle
2018-07-25$632.5MUndisclosedMultipleArticle